GV550

Phase 2Small molecule

LLaboratoires Thea

GV550 is one of 16 small molecule programs targeting Keratoconjunctivitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconjunctivitisActive, not recruiting

KeratoconjunctivitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Keratoconjunctivitis

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

—2

Lotemax

BBausch & Lomb Incorporated

Approved

2 3

Prograf

VVeloxis Pharmaceuticals

Approved

2 4

Decadron

AAspen Global Incorporated

Approved

1 5

Cyclosporine a

Novartis

Approved

1 6

FK506

Astellas

Phase 3

2 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 8

Ciclosporin

Novartis

Phase 2

1 9

Tobramycin and Dexamethasone

BBausch & Lomb Incorporated

Phase 3

2 10

NOVA22007

SSanten Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratoconjunctivitis1 trial

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

Completed·LLaboratoires Thea·Phase 2·NCT01156025·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GV550. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GV550 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GV550. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laboratoires Thea company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLaboratoires Thea

GV550

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratoconjunctivitis1 trial

References

Drug Info

Quick Facts

Related News